Active Biotech AB (publ) is a Sweden-based Company, which develops pharmaceutical products within medical areas where the immune defense is important, including cancer and inflammatory diseases. The project portfolio comprises both small, orally active immunomodulatory molecules and antibody-based immunotherapy.

Employees

Sector

Biotechnology & Medical Research

Calendar

02-11 - Q4 2025 Earnings Release

More about the company

Quotes

Date	Price	Change	Volume
25-12-12	0.0478 kr	-0.42%	9,981,185
25-12-11	0.0480 kr	-5.88%	12,371,170
25-12-10	0.0510 kr	-3.95%	12,628,110
25-12-09	0.0531 kr	-10.91%	19,935,890
25-12-08	0.0596 kr	-6.88%	6,668,379

Delayed Quote Nasdaq Stockholm, December 12, 2025 at 12:00 pm

More quotes

Income Statement and Estimates

More financial data

Net sales - Rate of surprise

Company calendar

Market Closed - Nasdaq Stockholm Other stock markets 12:00:00 2025-12-12 EST			5-day change	1st Jan Change
0.0478 ^SEK	-0.42%		-25.31%	-56.07%

12-11	New Public Short Seller in Active Biotech: Millennium Capital Management	FW
12-11	13 Stocks Reach New 52-Week Lows on the Stockholm Stock Exchange Today	FW

Capitalization	126M 13.57M 11.56M 10.8M 10.16M 18.7M 1.23B 20.43M 48.88M 579M 50.9M 49.83M 2.11B	P/E ratio 2025 *	-	P/E ratio 2026 *	-
Enterprise value	126M 13.57M 11.56M 10.8M 10.16M 18.7M 1.23B 20.43M 48.88M 579M 50.9M 49.83M 2.11B	EV / Sales 2025 *	-	EV / Sales 2026 *	1.65x
Free-Float	86.1%	Yield 2025 *	-	Yield 2026 *	-

12-11	New Public Short Seller in Active Biotech: Millennium Capital Management	FW
12-11	13 Stocks Reach New 52-Week Lows on the Stockholm Stock Exchange Today	FW
12-11	Stockholm Bullets - Munters Rises on Major New Order	FW
12-11	Active Biotech announces outcome of rights issue	RE
12-11	Active Biotech's Rights Issue Subscribed to 82.8 Percent - Underwriters Cover the Remainder	FW
12-10	Active Biotech's Only Public Short Seller Continues to Increase Its Position	FW
11-25	Active Biotech to Receive US Patent for Pharmaceutical Formulation with Tasquinimod	MT
11-25	Active Biotech: Patent to be granted in U.S.	RE
11-25	Active Biotech to Receive U.S. Patent for Tasquinimod-Related Pharmaceutical Formulation	FW
11-25	Active Biotech AB Announces Patent Related to A Pharmaceutical Formulation of Tasquinimod Will Be Granted in the US	CI
11-24	Active Biotech Publishes Preclinical Data on Tasquinimod in Myelofibrosis	FW
11-24	Active Biotech Reports Positive Preclinical Data for Tasquinimod	FW
11-24	Active Biotech Announces Preclinical Data with Tasquinimod in Myelofibrosis	CI

10-20	Stockholm Bullets - Karnell rises on buy recommendation	FW
07-08	Analysguiden Raises Target Value for Active Biotech Following Completion of Phase 1 Study	FW
02-14	Redeye lowers motivated value for Active Biotech to SEK 0.34 (0.40)	FW
01-02	Precise and Isofol 2024 winners on Nasdaq Stockholm, Xbrane and Fingerprint losers of the year	FW
11-19	Redeye lowers motivated value for Active Biotech to SEK 0.40 (0.50)	FW

Active Biotech AB Stock

Equities

ACTI

SE0001137985

Biotechnology & Medical Research

Valuation: Active Biotech AB

Chart: Active Biotech AB

Latest news: Active Biotech AB

Analysts' recommendations: Active Biotech AB

Press Releases: Active Biotech AB

News in other languages: Active Biotech AB

Quotes and Performance

Course Extremes

Managers and Directors: Active Biotech AB

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Net sales - Rate of surprise

12-10	Active Biotech announces outcome in the rights issue	AQ
11-25	Active Biotech : patent related to a pharmaceutical formulation of tasquinimod will be granted in the US	PU
11-25	Active Biotech’s patent related to a pharmaceutical formulation of tasquinimod will be granted in the US	AQ
11-25	Active Biotech : The subscription period in Active Biotech's rights issue begins today	PU
11-25	The subscription period in Active Biotech’s rights issue begins today	AQ

15-04-16	Ipsen : L'abandon du traitement du cancer de la prostate sanctionné
13-10-09	IPSEN : nouveau paiement d'étape de 12 millions d'euros à Active Biotech pour le Tasquinimod
12-12-10	IPSEN : et Active Biotech achèvent le recrutement pour l'étude phase III avec tasquinimod
12-05-18	BNP PARIBAS : INDICES : Le CAC 40 réduit sa perte à la mi-journée
12-05-18	IPSEN : résultats positifs d'une étude sur le tasquinimod

1 day	-0.42%
1 week	-25.31%
Current month	-18.15%
1 month	-39.80%
3 months	-71.95%
6 months	-79.96%
Current year	-56.07%

1 week	0.05	0.07
1 month	0.05	0.1
Current year	0.05	0.34
1 year	0.05	0.34
3 years	0.05	1.48
5 years	0.05	2.35
10 years	0.05	21.9

Manager	Title	Age	Since
Helén Tuvesson CEO	Chief Executive Officer	63	2017-06-30
Hans Kolam DFI	Director of Finance/CFO	74	1999-12-31
Erik Vahtola CTO	Chief Tech/Sci/R&D Officer	-	2021-12-31

Director	Title	Age	Since
Karl Peter Thelin BRD	Director/Board Member	69	2011-04-06
Michael Shalmi CHM	Chairman	60	2019-05-22
Uli Alf Hacksell BRD	Director/Board Member	75	2019-05-22

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
ACTIVE BIOTECH AB	-0.42%	-25.31%	-62.18%	-95.28%	13.57M
ARGENX SE	-0.48%	-2.31%	+29.68%	+105.96%	54.11B
INSMED INCORPORATED	+0.91%	-3.43%	+175.04%	+885.05%	42.02B
WUXI APPTEC CO., LTD.	+0.70%	+4.04%	+66.46%	+19.35%	39.6B
BIONTECH SE	-1.24%	-1.50%	-21.24%	-46.81%	22.8B
GENMAB A/S	-1.52%	-0.84%	+40.08%	-36.97%	19.5B
WUXI BIOLOGICS (CAYMAN) INC.	0.00%	+2.64%	+88.09%	-34.80%	17.76B
AKESO, INC.	+6.05%	+0.32%	+95.60%	+196.08%	14.73B
SUMMIT THERAPEUTICS INC.	-2.33%	-4.04%	-1.46%	+349.36%	13.55B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+5.03%	-4.65%	+133.80%	-	13.14B
Average	+0.67%	-3.64%	+54.39%	+149.10%	23.72B
Weighted average by Cap.	+0.45%	-1.16%	+69.98%	+218.24%

	2025 *	2026 *
Net sales	-	76.5M 8.24M 7.02M 6.55M 6.17M 11.35M 746M 12.4M 29.67M 352M 30.9M 30.25M 1.28B
Net income	-35.6M -3.83M -3.27M -3.05M -2.87M -5.28M -347M -5.77M -13.81M -164M -14.38M -14.08M -597M	45.6M 4.91M 4.18M 3.91M 3.68M 6.77M 445M 7.39M 17.69M 210M 18.42M 18.03M 765M
Net Debt	-	-